One thing I forgot in my last post. From the articles on Vascular Dementia that BDAZ gave us links to earlier in the week there is not a single medication at this time to deal with this problem. With zero competition that could be a lucrative market. Of course we first have to pass BoM and get good numbers on that secondary study for this to be worth anything. Waiting for the trial to complete is a nail biter at this time.
tada